This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94±4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. The last imatinib doses in chronic, accelerated and blastic phases were 609.72±171.29, 714.29±106.90, and 569.23±160.13, respectively. Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively. Molecular response was evaluated by bcr/abl transcript levels in RT-PCR. Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases. Of 99 patients 77 (77.8%) were alive. 16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis. No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events. Most patients had complete hematological response. Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects.
INTRODUCTION
Chronic myeloid leukemia (CML) has been defined as the malignant clonal disease of hematopoietic stem cells resulting in detection of increased numbers of myeloid cells, erythroid cells and platelets in peripheral blood, and myeloid hypercellularity in bone marrow. 1 It is very well documented that the expression of constitutively activated tyrosine kinase, which is a product of BCR-ABL, is underlying reason for CML phenotype. 2, 3 The reciprocal translocation between chromosomes 9 and 22 produces the shortened 22q known as the Philadelphia chromosome (Ph) and the new fusion gene is called as BCR-ABL fusion gene. 4 The typical clinical presentation of CML is seen in 3 different clinical phases; chronic phase (CP), accelerated phase (AP) and blastic phase (BP). 5 Without appropriate treatment, newly diagnosed chronic phase CML patients would eventually progress to accelerated and finally blastic phase. BP is of mainly myeloid phenotype in almost two third of patients and of lymphoid phenotype in most of the remaining patients. 6 BP of the disease in all forms have poor prognosis with overall survival of 3 to 6 months. 7 Most of the patients have been diagnosed in chronic phase. 8 Although the Ph chromosome and BCR-ABL transcript positivities have been major laboratory determinants of CML, this phenomenon is also detectable in acute lymphoblastic leukemia (ALL). ALL is the most common type of leukemia in children; ALL is also diagnosed in adults with less frequency and incidence, and has a second peak over the age of 70 years. 9 Chromosomal abnormalities have been documented in the course of ALL, and approximately 20-30% of adult ALL patients present with Ph abnormality. 10 The Ph positivity increase with age, being greater in older patients compared to young adults and children. 11 Regardless of the age, Ph (+) ALL, whether in adult or in children, has poorer prognosis compared to patients without this chromosomal abnormality. 12 The use of imatinib in the treatment of Ph (+) leukemias has been a milestone in the treatment of hematological malignancies. The tyrosine kinase activity of BCR-ABL is the main therapeutic target of imatinib that is the first tyrosine kinase inhibitor (TKI) used in the treatment of CML. It also inhibits the activity of c-kit, ARG and platelet derived growth factor receptors. 13 A large phase III randomized trial, known as IRIS, has provided the clinical and scientific background for the use of imatinib in the treatment of Ph (+) leukemias.
14 At a median follow-up of 19 months, the rate of complete cytogenetic response (CCyR) in the imatinib-treated patients was 94%compared with a CCyR of 8.5% achieved by patients on IFN-alpha and cytarabine. According to the 5-years results of IRIS study, only 68% of the patients in CCyR still remained on imatinib therapy. 15 The large use of imatinib in the treatment of Ph (+) leukemias have also created a new terminology like imatinib-intolerance and imatinib-resistance, and molecular pathogenesis of this new definitions have been clearly described in many studies. [16] [17] [18] The main mechanism for imatinib resistance has been clearly documented as the mutations occurred under the treatment of imatinib. 8 These definitions and the clinical results of either intolerance or resis-tance have implemented the need for new TKIs. Dasatinib is an SRC-family TKI that is structurally different from imatinib. 19 It has activity against many of the mutant forms of BCR-ABL, which are resistant to imatinib and this activity has resulted in the use of dasatinib in the treatment of CML and Ph (+) ALL. Its ability to bind both the inactive and active forms of BCR-ABL provides broader spectrum. 20 The Phase II START (SRC/ABL Tyrosine kinase inhibition Activity Research Trials of dasatinib) program contains the largest and most comprehensive study of dasatinib in the treatment of Phpositive leukemias to date. [21] [22] [23] [24] [25] It included 5 separate arms (C, A, B, L and R) that evaluated the effects of dasatinib in patients with CML or Ph (+) ALL at different stages who were classified as imatinib-resistant or -intolerant. START-C, A, B and L studies were designated as open-label, nonrandomized and with non-comparative arms and in these trials, dasatinib treatment was started with 70 mg BID. The dose could be escalated up to 90 or 100 mg BID in case of poor initial response or decreased to 50 or 40 mg BID in the patients with persistent drug-related toxicity. 26 The results of START Phase II trials showed that dasatinib was an effective treatment regimen in CML and Ph+ALL diseases and reported adverse events during dasatinib treatment were relatively low and tolerable. Dasatinib has been approved by FDA in 2006 for the use as a single agent in the treatment of adults with CML (CP, AP or BP [myeloid or lymphoid]) or with Ph-positive acute lymphoblastic leukemia (ALL), with resistance or intolerance to prior therapy, including imatinib ( Figure 1 ). 27 In Turkey, due to quite long registration and reimbursement procedures and local regulations, dasatinib was not on the market until 15 August 2008. However, certain numbers of patients have shown imatinib resistance or intolerance during or before this period. Compassionate use programs (CUP) are intended to facilitate the patient access for unmet needs during registration and reimbursement procedures. BMS has started a CUP to provide dasatinib to the patients who were defined as the imatinib-resistant or -intolerant by the primary physician according to the international and largely accepted guidelines at the second part of 2006. By using this compassionate use program, consistent policy across participating centers in Tur- 
MATERIALS AND METHODS

Patients
The primary objective of this compassionate use program was to provide access to dasatinib to as many patients as possible during the application period across in all region of Turkey. Between November 2006 and April 2008 114 patients from 27 different centers across Turkey were enrolled to CUP by single patient based application. This program was not performed either as a part of any clinical trials or in the setting of clinical trial. The clinical and laboratory status of the patients was followed-up by their primary physicians. The criterions for the start of the dasatinib treatment were based on the NCCN and ELN CML guidelines. The primary physicians of the patients were asked to fill out the forms containing the demographic data of the patients, the disease status, and the certain indication(s) for dasatinib requirement under the guidance of current guidelines. These forms were signed by the physicians and sent to BMS center. Patients were also required to give written informed consent. They were also informed and educated for the potential outcomes and side effects which could be detected under dasatinib treatment.
Patients' Inclusion
Patients ≥ 18 years with the following disease characteristics were defined as the eligible for the dasatinib treatment under the CUP: dasatinib is indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib. Dasatinib is also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy
Patients' Exclusion
Patients were excluded if they had prior history of pleural effusion with any reason, ECOG performance status >3, grade 3-4 cardiac disease as defined by the New York Heart Association criteria, serum creatinine, liver transaminase, or bilirubin above the upper limit of normal range, females with pregnancy, serious concomitant medical condition, history of noncompliance to prior medical approaches.
Treatment
Dasatinib (Sprycel‚, BMS) was supplied as 50-and 20 mg tablets. CML-CP, AP, BP, and Ph (+) ALL patients started to use dasatinib at a dose 70 mg BID. If the patient was evaluated as unresponsive based on the published and accepted current literature, dose escalation up to 200 mg/ day was allowed. In case of any grade 3-4 adverse events reported by primary physicians, dose reduction from 70 mg BID to 50 mg BID was applied. Other dose and treatment modifications were performed if needed for each case by using the data from clinical phase studies and large trials.
Dasatinib treatment with was continued until death, disease progression under dasatinib therapy (for CML-CP patients), development of serious toxicity, lack of efficacy proven clinically and with laboratory tests such as cytogenetic and molecular methods, or whenever dasatinib became commercially available and the patient was able to continue therapy via prescription.
Evaluation of the Patients
Patients were evaluated according to the age, gender, median time from the diagnosis, the reasons for dasatinib treatment, and stage of the disease, last imatinib doses, last treatment status with dasatinib, adverse events under dasatinib treatment, and response status to dasatinib treatment retrospectively.
The independent Clinical Research Organization (CRO) company was hired to fill out the questionnaire forms containing the each section above mentioned which are prepared by the Turkish CML Study Group. CRO has visited all centers where the patients were enrolled to the program and filled these forms based on the patients' files. Additionally, serious adverse event forms reported by primary physicians and the application forms required for the enrollment to the program as a routine base were used for further patients' information.
Endpoints
The primary endpoint of this program was to provide patient access to dasatinib before registration, and to determine hematological response rate, the number of treatment related adverse events and treatment discontinuation rates. Also, dose modifications, disease status under dasatinib treatment, cytogenetic and molecular responses was analyzed and evaluated according to the available patient data.
Statistical Analysis
All the statistical analyses were performed by using the data obtained from the patients' files recorded by primary physicians. Special form was designed to summarize the required data and completed by independent CRO. Any patient who received at least one dose of dasatinib was included into evaluation. Demographics, diseases status at baseline, time from diagnosis, duration of prior treatment, the reasons for switching therapy to dasatinib, and the last imatinib doses were summarized for all leukemic patients Additionally, the last disease status, mortality rates, discontinuation rates, and the reported adverse events, dose modifications were also presented.
Time to progression (TTP) was defined as the time between starting the drug and either discontinuation of drug for any reason or death. Overall survival (OS) was defined as the time period between the entry of therapy to death because of any reason as well as any death reported after drug stopped. TTP and OS were performed by using Kaplan-Meier method. (Table 1) . The hematologic response status of CML patients was categorized based on phases. Table 2 showed that 66.3 % of patients in chronic phase and 44.4 % in accelerated phase have complete hematologic response (CHR) and 50% death rate in blastic phase. Cytogenetic analysis results could not be obtained from all patients due to different enrollment date to the CUP. Molecular response (MR) status was evaluated based on bcr/abl transcript levels by using RT-PCR. 27.0 % of the cases in chronic, 11.1% in accelerated and 18.8% in blastic phase have complete molecular response (Table 3) which is defined disappearance of bcr-abl transcripts. Blood samples were obtained from all patients and analyzed for laboratory evaluations. While the most adverse reaction was hematological during the dasatinib treatment, fluid retention including pleural edema, infectious problems, gastrointestinal side effects, skin problems and neurological side effects were also observed. Table 4 showed the summary of treatment-related adverse events occurring during the dasatinib treatment. Thrombocytopenia is the most prominent hematological side effects with the ratio of 24.3%, while leucopenia and neutropenia was also reported with 20.2%. Pleural effusion, which is the most common non-hematological side effect, was detected as 8.5% of total side effects. Of 114 patients, 83 patients' data were eligible for progression analysis. While disease stabilization or remission were obtained in 76 of 83 patients (91.6%), progression was determined in 7 of 83 patients (8.4%) and progression time was 5 to 27 months ( Figure 2 and sepsis. Other reasons for death are classified as pancytopenia, chronic renal failure, relapsed disease, and graft rejection after allogeneic transplantation. No patients died because of any side effects of treatment. All calculations were based on 99 patients who were eligible for survival analysis. Survival analysis is based on Kaplan-Meier survival function, which takes into account the exitus and living subjects. The date of dasatinib initiation for all subjects, date of exitus for exitus subjects and the treatment period of living subjects are considered here. 77 of 99 patients (77.8%) were alive and 22 (%22.2) died. Figure 3 showed that 16th month-OS for 99 patients was 78% according to Kaplan-Meier survival analysis. published the results of international expanded access program of imatinib, the designation and contents of that publication is completely different from our study. 28 Since the primary aim and the endpoint have not been defined as the determination of either molecular or cytogenetic responses, the clinicians were asked to provide if they have available data. However, the central authorities and the BMS Company requested the clinicians to fill the adverse event forms appropriately. One of the major endpoint for our study was described the hematological response rate at the end of the CUP. The CHR was calculated as 66.3% in our CP-CML patients. In START-C study, dasatinib was evaluated in 387 CP-CML patients and these patients were followed-up for a median of 15.2 months. 21 CHR was found to be as 91% in patients treated with dasatinib in START-C clinical study. The CHR in our CUP program was relatively lower compared to START-C study, but the heterogeneity of our patients could explain this difference. Moreover, similar difference can be detected also in molecular response status. Although the cytogenetic response status was evaluated and found to be as 59% MCyR in START-C study, CMR was found to be as 27.0% in our CP-CML patients treated under CUP. Although the molecular response rate does not directly reflect the cytogenetic response rate, it is highly possible to say that the response rate was lower in our CUP. However, as mentioned before, the heterogeneity of patients and also the heterogeneity of the laboratories which performed these analyses could be the potential reason for this difference. Also, CUP is not designated as the clinical study and the results don't illustrate the results of clinical study. In our report, CHR was found to be as 44.4% in patients with AP-CML patients. In START-A study, the effectiveness of dasatinib was evaluated in patients with AP-CML patients and CHR was obtained in 45% of patients. 23 The CHR in our patients with AP-CML patients was similar with START-A study. However the number of patients in our CUP is relatively less than the START-A study.
RESULTS
Between
Most of the reported side effects under treatment with dasatinib are mild-to-moderate. In almost all of the phase II clinical trials, various degrees of side effects were reported and the most common drug-related toxicities were fluid retention including pleural effusion, diarrhea, skin rash, headache, hemorrhage fatigue, nausea and dyspnea. 29 Pleural effusion, edema and other type of fluid retention events were seen with different ratios during dasatinib clinical trials. Especially the edema occurred during dasatinib treatment was grade 1-2 and was successfully managed with diuretics. It was reported as 4% in our chronic-phase CML patients which is similar to results obtained from other studies. Pleural effusion, which is accepted as the most troublesome side effect of dasatinib, was detected with the ratio of 8.5% in our patients with chronicphase CML. Grade 3-4 pleural effusions were reported with the ratio of 4-15 %, and the incidence of any grade of pleural effusions were 13-27% in START studies. [21] [22] [23] [24] [25] Other fluid retention events were uncommon. Edema, pleural effusions and other fluid retention events could be successfully manipulated by dose interruption, reduction or modifications of the treatment schedules. Corticosteroids may be helpful, but no steroid need was reported in our patients. Since these patients have hematological malignancies and prior treatments, it is highly expected to see some level of hematologic toxicity. Treatment with dasatinib may result in grade 3-4 thrombocytopenia, neutropenia and anemia. Myelosupression as an anticipated therapeutic effect of dasatinib could be detected in patients with advanced stage of CML or Ph+ ALL. Hopefully, it is re-versible with dose modifications or short term interruptions. In our study, any degree of bone marrow suppression as cytopenia were reported with the ratio of 55-68% in patients treated with dasatinib. However, none of the patients died because of hematological side effects and all of these events were reversible by interventions as abovementioned. The survival analysis of our patients has some promising results. According to Kaplan-Meier analysis of our available 99 patients, OS of our group 78% for the patients treated with dasatinib under CUP at 16th month. Since the OS was estimated 66-82% in START studies, our results could be accepted similar to these clinical studies. Optimal management of imatinib resistant or intolerant Ph+CML is a growing problem in last five years. [30] [31] [32] Dasatinib has been the first tyrosine kinase inhibitor approved for use in CML and Ph+ ALL in patients resistant or intolerant to imatinib. In conclusion, evaluable results from Turkish dasatinib CUP were accordingly with clinical trial results previously reported. This CUP is not a clinical trial, therefore the patients treated with dasatinib was heterogeneous. As enrollment date to the CUP is different for each patient, variable treatment durations may possibly affect response rates and definition. However, dasatinib treatment in Turkish patients with CML was well tolerated and resulted in favorable outcomes with only mild side effects in most cases during the period of observation of patients with accessible data so far.
